The COG concerns are mostly in Julie’s talk, the SIOPEN one’s are the same mentioned by my Oncologist. David Zeigler is in charge of DFMO relapse trial that are running in Sydney.
Perhaps have a chat with your team about DFMO and get some feedback from them as well?